b'<style type="text/css">\r\n\t\t\t.cs2E86D3A6{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt}\r\n\t\t\t.cs5925EB86{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:bold;font-style:normal;}\r\n\t\t\t.cs95E872D0{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt}\r\n\t\t\t.csDD5E5F52{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.csED7826F6{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:14pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.csE0B838BE{text-align:justify;text-indent:-86pt;margin:0pt 0pt 0pt 86pt}\r\n\t\t\t.csA16174BA{color:#000000;background-color:transparent;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.cs9224F58F{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csC970676{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.cs5ADD8C59{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.csE2DB38B2{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:bold;font-style:italic;}\r\n\t\t\t.cs5D3E032C{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:9pt;font-weight:normal;font-style:normal;text-decoration: line-through;}\r\n\t\t\t.cs41ED3027{text-align:center;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csE3E0FE0B{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:normal;font-style:italic;}\r\n\t\t\t.cs5CA3ADAD{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 54pt;line-height:12pt;mso-line-height-rule:exactly}\r\n\t\t\t.csD15247B9{text-align:left;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:1.5}\r\n\t\t\t.csF0A1D375{text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 0pt;line-height:1.5}\r\n\t\t\t.cs2C11128C{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:12pt;font-weight:normal;font-style:normal;}\r\n\t\t\t.cs2222D344{text-align:center;text-indent:0pt;margin:3pt 0pt 3pt 0pt}\r\n\t\t\t.csE4480EBF{color:#000000;background-color:transparent;font-family:\'Century Schoolbook\';font-size:10pt;font-weight:bold;font-style:normal;text-transform:uppercase;}\r\n\t\t\t.csDEEE74F6{text-align:left;text-indent:-27pt;margin:0pt 0pt 0pt 27pt;line-height:1.5}\r\n\t\t</style>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\r\n\r\n\t\t<p class="cs2E86D3A6"><span class="cs5925EB86">HB 1290-FN - AS INTRODUCED</span></p><p class="cs2E86D3A6"><span class="cs5925EB86">&nbsp;</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">2022 SESSION</span></p><p class="cs95E872D0" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t22-2677</span></p><p class="cs95E872D0" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t05/04</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 108pt;"><span class="csDD5E5F52">HOUSE BILL\t</span><span class="csED7826F6">1290-FN</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraft0"><span class="csDD5E5F52">establishing a task force on precision medicine and biomarker testing.</span></a></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE" style="tab-stops:left 86.45pt;"><span class="csDD5E5F52">SPONSORS:\tRep. Rogers, Merr. 28</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE" style="tab-stops:left 86.45pt;"><span class="csDD5E5F52">COMMITTEE:\tHealth, Human Services and Elderly Affairs</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csA16174BA">-----------------------------------------------------------------</span></p><p class="cs95E872D0" style="tab-stops:left 90pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">ANALYSIS</span></p><p class="cs2E86D3A6"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs9224F58F" style="tab-stops:left 18pt left 86.45pt;"><span class="csDD5E5F52">\tThis bill establishes a task force on precision medicine and biomarker testing.</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs95E872D0"><span class="csDD5E5F52">- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - </span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">Explanation:\tMatter added to current law appears in </span><span class="csE2DB38B2">bold italics.</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">\t\tMatter removed from current law appears [</span><span class="cs5D3E032C">in brackets and struckthrough.</span><span class="cs5ADD8C59">]</span></p><p class="csC970676" style="tab-stops:left 14.4pt left 82.8pt;"><span class="cs5ADD8C59">\t\tMatter which is either (a) all new or (b) repealed and reenacted appears in regular type.</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t22-2677</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">\t05/04</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csDD5E5F52">STATE OF NEW HAMPSHIRE</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csE3E0FE0B">In the Year of Our Lord Two Thousand Twenty Two</span></p><p class="csC970676" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraft1"><span class="csDD5E5F52">establishing a task force on precision medicine and biomarker testing.</span></a></p><p class="cs5CA3ADAD" style="tab-stops:left 396pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs41ED3027" style="tab-stops:left 396pt;"><span class="csE3E0FE0B">Be it Enacted by the Senate and House of Representatives in General Court convened:</span></p><p class="csD15247B9"><span class="csDD5E5F52">&nbsp;</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt1"></a><span class="csDD5E5F52">1 &nbsp;Findings.  The legislature finds that 60 percent of medical treatments in preclinical development rely on biomarker data. &nbsp;In fact, biomarker testing is available for an ever-increasing range of conditions and diseases, but patient access to these tests is not keeping pace with the rate of innovation and a lack of awareness among providers and patients, a lack of common terminology, and deficient coverage policies by both public and private payers are preventing effective adoption and integration of biomarker testing. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="CHAPT"></a><span class="csDD5E5F52">2 &nbsp;New Section; Task Force on Precision Medicine and Biomarker Testing. &nbsp;Amend RSA 126-A by inserting after section 15-a the following new section:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t126-A:15-b &nbsp;Task Force on Precision Medicine and Biomarker Testing.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tI. &nbsp;The health and human services oversight committee, established in RSA 126-A:13, shall convene a precision medicine and biomarker testing task force.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tII. &nbsp;The task force shall study and make recommendations to the legislature to support improved awareness, understanding, and access to precision medicine and biomarker testing by patients, health care providers, employers, and public and private payers.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIII. &nbsp;The task force shall be comprised of the following members, appointed in accordance with this paragraph:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(a) &nbsp;The oversight committee shall jointly appoint:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(1) &nbsp;One representative of an academic medical center conducting research on biomarker testing and/or personalized medicine.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(2) &nbsp;One expert who is a researcher in molecular diagnostics/ biomarker testing.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(3) &nbsp;One molecular pathologist.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(4) &nbsp;One expert who is a health care provider who utilizes biomarker tests to diagnose, treat and/or monitor patients.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;House members of the oversight committee shall appoint:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(1) &nbsp;One health technology researcher who specializes in personalized medicine. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(2) &nbsp;One representative of a patient advocacy organization.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(3) &nbsp;One representative of a diagnostic company such as a reference laboratory or biomarker test manufacturer.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(c) &nbsp;Senate members of the oversight committee shall appoint:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(1) &nbsp;One representative of a health insurance plan or employer that is self-insured.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(2) &nbsp;One representative of a national organization which publishes clinical guidelines on biomarker testing and/or personalized medicine or their appointee. </span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t\t(3) &nbsp;One member of a community or community organization impacted by health inequities related to biomarker testing and/or precision healthcare.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(d) &nbsp;The commissioner of the department of health and human services, or the commissioner&rsquo;s designee, shall serve as an ex-officio member of the task force.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(e) &nbsp;The oversight committee shall jointly select the chairperson of the task force.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tIV. &nbsp;The task force shall:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(a) &nbsp;Solicit definitions of &ldquo;biomarker testing,&rdquo; &ldquo;precision medicine,&rdquo; and &ldquo;molecular testing,&rdquo; and any other terms as determined by the task force.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;Review reports or studies on the current status of precision medicine and biomarker testing, how the science is evolving, and patients&rsquo; and providers&rsquo; experiences in accessing and providing biomarker testing and personalized health care.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(c) &nbsp;Examine barriers to the use of biomarker testing across the continuum of consumer and patient needs focused on diagnosis, treatment decisions, and post-treatment monitoring of disease, including but not limited to: lack of awareness of biomarker tests generally, inconsistency of terminology, no or low reimbursement for providers, lack of coverage or restrictive utilization management by payers, and level of patient and provider understanding of the use of biomarker testing in measuring indicators of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(d) &nbsp;Study the role of clinical practice guidelines in health care provider and payer decision making related to biomarker testing, especially when evidence-based tests are available, but clinical guidelines are not yet developed.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(e) &nbsp;Identify opportunities to expand awareness, education, understanding and usefulness of biomarker testing and precision medicine to improve care and reduce unnecessary health care spending.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(f) &nbsp;Make and report findings for policies or actions to improve awareness, education, and coverage that would optimize the use of biomarker testing and precision medicine for residents of New Hampshire.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tV. &nbsp;The task force may:</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(a) &nbsp;Establish subcommittees as necessary to fulfill its duties.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t\t(b) &nbsp;Solicit expert testimony to fulfill its duties.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tVI. &nbsp;A member or an ex officio member of the task force shall not receive compensation as a member of the task force; but shall receive mileage at the rate paid to state employees when attending to the duties of the task force.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tVII. &nbsp;On or before November 1, 2024, the task force shall submit a report of its findings and recommendations to the governor and legislature.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt2"></a><span class="csDD5E5F52">3 &nbsp;Repeal. &nbsp;RSA 126-A:15-b, relative to the task force on precision medicine and biomarker testing, is repealed.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t</span><a name="Chapt3"></a><span class="csDD5E5F52">4 &nbsp;Effective Date.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\tI. &nbsp;Section 3 of this act shall take effect November 1, 2024.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="csDD5E5F52">\t\t II. &nbsp;The remainder of this act shall take effect upon its passage.</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="cs2C11128C">&nbsp;</span></p><p class="cs95E872D0" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt left 108pt left 244.8pt;"><a name="bkFiscalNote"><span class="csDD5E5F52">\t\t\t\t\t\t\t\t\t\t\tLBA</span></a></p><p class="cs95E872D0" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt left 108pt left 244.8pt;"><span class="csDD5E5F52">\t\t\t\t\t\t\t\t\t\t\t22-2677</span></p><p class="cs95E872D0" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt left 108pt left 244.8pt;"><span class="csDD5E5F52">\t\t\t\t\t\t\t\t\t\t\t10/18/21</span></p><p class="cs95E872D0"><span class="csDD5E5F52">&nbsp;</span></p><p class="cs2222D344"><span class="csE4480EBF">HB 1290-FN- FISCAL NOTE</span></p><p class="cs2222D344"><span class="csE4480EBF">AS INTRODUCED</span></p><p class="csE0B838BE" style="tab-stops:left 85.5pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="csE0B838BE"><span class="csDD5E5F52">AN ACT\t</span><a name="bkTitleDraftFN1"><span class="csDD5E5F52">establishing a task force on precision medicine and biomarker testing.</span></a></p><p class="csD15247B9" style="tab-stops:left 85.5pt;"><span class="cs5925EB86">&nbsp;</span></p><p class="csD15247B9" style="tab-stops:left 27pt left 85.5pt;"><span class="cs5925EB86">FISCAL IMPACT:</span></p><p class="csDEEE74F6" style="tab-stops:left 27pt left 85.5pt;"><span class="cs5925EB86">\t</span><span class="csDD5E5F52">The Legislative Budget Assistant has determined that this legislation, as introduced, has a total fiscal impact of less than $10,000 in each of the fiscal years 2022 through 2025.</span></p><p class="csD15247B9" style="tab-stops:left 27pt;"><span class="csDD5E5F52">&nbsp;</span></p><p class="csD15247B9" style="tab-stops:left 27pt;"><span class="cs5925EB86">AGENCIES CONTACTED:</span></p><p class="csD15247B9" style="tab-stops:left 27pt;"><span class="csDD5E5F52">\tNone</span></p><p class="csF0A1D375" style="tab-stops:left 18pt left 36pt left 54pt left 72pt left 90pt;"><span class="cs2C11128C">&nbsp;</span></p>'